Search
Anidulafungin
go.drugbank.com/drugs/DB00362ApprovedAnidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366.
Atidarsagene autotemcel
go.drugbank.com/drugs/DB17538ApprovedInvestigational[L45191] Libmeldy was granted orphan designation by the EMA in April 2007, and was issued a marketing authorization in the EU in December 2020 for the treatment of certain manifestations of metachromatic
MK-8189
go.drugbank.com/drugs/DB19153InvestigationalMK-8189 is under investigation in clinical trial NCT04624243 (Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)).
Pancuronium
go.drugbank.com/drugs/DB01337ApprovedAs a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.
Cyclandelate
go.drugbank.com/drugs/DB04838ApprovedWithdrawnCyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.
Dabigatran etexilate
go.drugbank.com/drugs/DB06695ApprovedInvestigational[A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022]
Inulin
go.drugbank.com/drugs/DB00638ApprovedInvestigationalNutraceuticalA starch found in the tubers and roots of many plants. Since it is hydrolyzable to fructose, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function.
Foreskin keratinocyte (neonatal)
go.drugbank.com/drugs/DB10772ApprovedOrcel, another skin substitute, is similar to Apligraf since it contains both fibroblasts and keratinocytes derived from neonatal foreskin, but in addition, utilizes a type I collagen sponge as its matrix … Apligraf has been useful in the treatment of venous leg ulcers and diabetic foot ulcers, by increasing rates of wound healing and decreasing the time required for closure of wounds [L2452].
Colfosceril palmitate
go.drugbank.com/drugs/DB09114ApprovedWithdrawn[T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990.[L1109] Nowadays colfosceril palmitate is under the state of canceled post-marketing.
Verapamil
go.drugbank.com/drugs/DB00661ApprovedInvestigational[A188514] It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications … racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but